Molecular Partners Ag (MOLN) EBITDA Margin Growth (1y) (2021 - 2026)
Molecular Partners Ag (MOLN) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 7,666.00 |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1,238.00 |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 2,002.00 |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | -3,558.00 |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 29,091.00 |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | -1,651.00 |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,306.00 |
| Dec 31, 2025 | -96.40 Mn |
| Sep 30, 2025 | -9,957.00 |
| Jun 30, 2025 | 102.99 Bn |
| Mar 31, 2025 | 30,307.00 |
| Dec 31, 2024 | 109.77 Mn |
| Sep 30, 2024 | 45,061.00 |
| Jun 30, 2024 | -103.00 Bn |
| Mar 31, 2024 | -41,399.00 |
| Dec 31, 2023 | -91,842.00 |
| Sep 30, 2023 | -45,061.00 |
| Jun 30, 2023 | -512,467.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 8,176.00 |
| Sep 30, 2022 | 35,211.00 |
| Jun 30, 2022 | 129,397.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 3.00 |
| Sep 30, 2021 | -35,211.00 |